{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T16:38:41Z","timestamp":1793723921888,"version":"4.6.1"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,8,6]],"date-time":"2020-08-06T00:00:00Z","timestamp":1596672000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,8,6]],"date-time":"2020-08-06T00:00:00Z","timestamp":1596672000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100013526","name":"Defence Health Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013526","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001193","name":"Sir Edward Dunlop Medical Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001193","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Psychiatry"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Most patients with Posttraumatic Stress Disorder (PTSD) suffer residual symptoms following first-line treatment. Oxidative stress has been implicated in the pathophysiology of PTSD. N-acetylcysteine (NAC) is a precursor of the brain\u2019s primary antioxidant, glutathione, and may diminish oxidative cellular damage. An 8-week pilot study of NAC in veterans with PTSD found that symptoms were significantly reduced in the NAC group compared to placebo. This study aims to confirm these findings with a larger sample in a double-blind, placebo-controlled trial to further explore the efficacy of NAC as an adjunctive therapy in treatment-resistant PTSD.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>A multicentre, randomised, double-blind, placebo-controlled trial for adult patients who still meet criteria for PTSD following first-line treatment. The intervention comprises either NAC as a fixed dose regime of 2.7\u2009g\/day (900\u2009mg three times daily) administered orally for 12\u2009weeks, or placebo. Standard care for PTSD will continue in addition, including other pharmacotherapies. Detailed clinical data will be collected at randomisation and weeks 4, 8, 12, 16, and 64 post-randomisation, with self-report measures completed weekly from baseline to 16\u2009weeks and at 64\u2009weeks post-randomisation. Blood-based biomarkers will be collected at baseline and 12\u2009weeks to assess the mechanism of effect. The primary outcome measure will be change in Clinician-Administered PTSD Scale for DSM-5 at 12\u2009weeks compared with baseline. Secondary outcomes will be change in quality of life, depression, anxiety, substance use and craving, and somatic symptoms. With 126 completed participants (63 per arm), the study is powered at 80% to detect a true difference in the primary outcome measure using a two-tailed analysis with alpha\u2009=\u20090.05, beta\u2009=\u20090.2.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Discussion<\/jats:title>\n<jats:p>This is the first multicentre, double blind, randomised, placebo-controlled trial of adjunctive NAC for treatment-resistant PTSD. NAC has an established safety profile, is readily available and easy to administer, and has a favourable tolerability profile, therefore making it an attractive adjunctive therapy. Inclusion of blood analyses to assess potential target engagement biomarkers of oxidative stress and neuroinflammation may help gauge the biological mechanisms of effect of NAC.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Trial registration<\/jats:title>\n<jats:p>ACTRN12618001784202, retrospectively registered 31\/10\/2018, URL: <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.anzctr.org.au\/Trial\/Registration\/TrialReview.aspx?id=376004\">http:\/\/www.anzctr.org.au\/Trial\/Registration\/TrialReview.aspx?id=376004<\/jats:ext-link>.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s12888-020-02793-9","type":"journal-article","created":{"date-parts":[[2020,8,6]],"date-time":"2020-08-06T09:03:16Z","timestamp":1596704596000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["A multi-centre, double-blind, 12-week, randomized, placebo-controlled trial to assess the efficacy of adjunctive N-Acetylcysteine for treatment-resistant PTSD: a study protocol"],"prefix":"10.1186","volume":"20","author":[{"given":"Alice","family":"Maier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita","family":"Dharan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gina","family":"Oliver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Berk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzy","family":"Redston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sudie E.","family":"Back","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Kalivas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chee","family":"Ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0992-1917","authenticated-orcid":false,"given":"Richard A.","family":"Kanaan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,8,6]]},"reference":[{"key":"2793_CR1","doi-asserted-by":"crossref","DOI":"10.1176\/appi.books.9780890425596","volume-title":"Diagnostic and statistical manual of mental disorders","author":"Association AP","year":"2013","unstructured":"Association AP. Diagnostic and statistical manual of mental disorders. 5th ed; 2013.","edition":"5"},{"issue":"5","key":"2793_CR2","doi-asserted-by":"crossref","first-page":"407","DOI":"10.3109\/00048674.2010.543654","volume":"45","author":"KL Mills","year":"2011","unstructured":"Mills KL, McFarlane AC, Slade T, Creamer M, Silove D, Teesson M, et al. Assessing the prevalence of trauma exposure in epidemiological surveys. Aust N Z J Psychiatry. 2011;45(5):407\u201315.","journal-title":"Aust N Z J Psychiatry"},{"issue":"18","key":"2793_CR3","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1001\/jama.298.18.2141","volume":"298","author":"CS Milliken","year":"2007","unstructured":"Milliken CS, Auchterlonie JL, Hoge CW. Longitudinal assessment of mental health problems among active and reserve component soldiers returning from the Iraq war. JAMA. 2007;298(18):2141\u20138.","journal-title":"JAMA."},{"issue":"2","key":"2793_CR4","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.pnpbp.2008.12.004","volume":"33","author":"W Berger","year":"2009","unstructured":"Berger W, Mendlowicz MV, Marques-Portella C, Kinrys G, Fontenelle LF, Marmar CR, et al. Pharmacologic alternatives to antidepressants in posttraumatic stress disorder: a systematic review. Prog Neuro-Psychopharmacol Biol Psychiatry. 2009;33(2):169\u201380.","journal-title":"Prog Neuro-Psychopharmacol Biol Psychiatry"},{"key":"2793_CR5","unstructured":"Department of Veterans Affairs and the Department of Defense. VA\/DoD Clinical practice guideline for the management of posttraumatic stress disorder and acute stress disorder, 3.0; 2017. p. 13\u201314."},{"issue":"4","key":"2793_CR6","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1002\/mhp.102","volume":"3","author":"E Savoca","year":"2000","unstructured":"Savoca E, Rosenheck R. The civilian labor market experiences of Vietnam-era veterans: the influence of psychiatric disorders. J Ment Health Policy Econ. 2000;3(4):199\u2013207.","journal-title":"J Ment Health Policy Econ"},{"issue":"1","key":"2793_CR7","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1023\/A:1024409200155","volume":"11","author":"DS Riggs","year":"1998","unstructured":"Riggs DS, Byrne CA, Weathers FW, Litz BT. The quality of the intimate relationships of male Vietnam veterans: problems associated with posttraumatic stress disorder. J Trauma Stress. 1998;11(1):87\u2013101.","journal-title":"J Trauma Stress"},{"issue":"1","key":"2793_CR8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/13811110903478997","volume":"14","author":"K Krysinska","year":"2010","unstructured":"Krysinska K, Lester D. Post-traumatic stress disorder and suicide risk: a systematic review. Arch Suicide Res. 2010;14(1):1\u201323.","journal-title":"Arch Suicide Res"},{"issue":"7","key":"2793_CR9","doi-asserted-by":"crossref","first-page":"536","DOI":"10.7205\/MILMED.169.7.536","volume":"169","author":"TC Buckley","year":"2004","unstructured":"Buckley TC, Mozley SL, Bedard MA, Dewulf AC, Greif J. Preventive health behaviors, health-risk behaviors, physical morbidity, and health-related role functioning impairment in veterans with post-traumatic stress disorder. Mil Med. 2004;169(7):536\u201340.","journal-title":"Mil Med"},{"key":"2793_CR10","unstructured":"Gros DF, Tuerk PW, Yoder M, Acierno R. Handbook of clinical psychology competencies, volume II: intervention and treatment for adults. New York: Springer; 2011."},{"issue":"11","key":"2793_CR11","first-page":"754","volume":"43","author":"J Cooper","year":"2014","unstructured":"Cooper J, Metcalf O, Phelps A. PTSD--an update for general practitioners. Aust Fam Physician. 2014;43(11):754\u20137.","journal-title":"Aust Fam Physician"},{"key":"2793_CR12","volume-title":"Australian guidelines for the treatment of acute stress disorder and posttraumatic stress disorder","author":"Health PACfPM","year":"2013","unstructured":"Health PACfPM. Australian guidelines for the treatment of acute stress disorder and posttraumatic stress disorder. Melbourne: Phoenix Australia; 2013."},{"issue":"10","key":"2793_CR13","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1017\/S1092852900022380","volume":"9","author":"MB Hamner","year":"2004","unstructured":"Hamner MB, Robert S, Frueh BC. Treatment-resistant posttraumatic stress disorder: strategies for intervention. CNS Spectr. 2004;9(10):740\u201352.","journal-title":"CNS Spectr"},{"issue":"Suppl 2","key":"2793_CR14","first-page":"34","volume":"67","author":"JR Davidson","year":"2006","unstructured":"Davidson JR. Pharmacologic treatment of acute and chronic stress following trauma: 2006. J Clin Psychiatry. 2006;67(Suppl 2):34\u20139.","journal-title":"J Clin Psychiatry."},{"key":"2793_CR15","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1007\/s40501-017-0130-0","volume":"4","author":"JA Starke","year":"2017","unstructured":"Starke JA, Stein DJ. Management of Treatment-Resistant Posttraumatic Stress Disorder. Curr Treat Options Psych. 2017;4:387\u2013403.","journal-title":"Curr Treat Options Psych"},{"issue":"5","key":"2793_CR16","doi-asserted-by":"crossref","first-page":"503","DOI":"10.2174\/187152706778559309","volume":"5","author":"JD Bremner","year":"2006","unstructured":"Bremner JD. Stress and brain atrophy. CNS Neurol Disord Drug Targets. 2006;5(5):503\u201312.","journal-title":"CNS Neurol Disord Drug Targets"},{"issue":"2","key":"2793_CR17","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.neuropharm.2011.02.027","volume":"62","author":"DG Baker","year":"2012","unstructured":"Baker DG, Nievergelt CM, O'Connor DT. Biomarkers of PTSD: neuropeptides and immune signaling. Neuropharmacology. 2012;62(2):663\u201373.","journal-title":"Neuropharmacology."},{"issue":"1\u20132","key":"2793_CR18","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.psychres.2015.05.036","volume":"229","author":"M Furtado","year":"2015","unstructured":"Furtado M, Katzman MA. Neuroinflammatory pathways in anxiety, posttraumatic stress, and obsessive compulsive disorders. Psychiatry Res. 2015;229(1\u20132):37\u201348.","journal-title":"Psychiatry Res"},{"issue":"4","key":"2793_CR19","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s00406-015-0638-5","volume":"266","author":"A Atli","year":"2016","unstructured":"Atli A, Bulut M, Bez Y, Kaplan I, Ozdemir PG, Uysal C, et al. Altered lipid peroxidation markers are related to post-traumatic stress disorder (PTSD) and not trauma itself in earthquake survivors. Eur Arch Psychiatry Clin Neurosci. 2016;266(4):329\u201336.","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"issue":"Pt 1","key":"2793_CR20","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1177\/0004563214528882","volume":"52","author":"L Borovac Stefanovic","year":"2015","unstructured":"Borovac Stefanovic L, Kalinic D, Mimica N, Beer Ljubic B, Aladrovic J, Mandelsamen Perica M, et al. Oxidative status and the severity of clinical symptoms in patients with post-traumatic stress disorder. Ann Clin Biochem. 2015;52(Pt 1):95\u2013104.","journal-title":"Ann Clin Biochem"},{"issue":"3","key":"2793_CR21","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.pscychresns.2014.09.007","volume":"224","author":"L Michels","year":"2014","unstructured":"Michels L, Schulte-Vels T, Schick M, O'Gorman RL, Zeffiro T, Hasler G, et al. Prefrontal GABA and glutathione imbalance in posttraumatic stress disorder: preliminary findings. Psychiatry Res. 2014;224(3):288\u201395.","journal-title":"Psychiatry Res"},{"key":"2793_CR22","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.psyneuen.2014.09.024","volume":"51","author":"DS Tylee","year":"2015","unstructured":"Tylee DS, Chandler SD, Nievergelt CM, Liu X, Pazol J, Woelk CH, et al. Blood-based gene-expression biomarkers of post-traumatic stress disorder among deployed marines: a pilot study. Psychoneuroendocrinology. 2015;51:472\u201394.","journal-title":"Psychoneuroendocrinology."},{"issue":"5","key":"2793_CR23","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1046\/j.1471-4159.2003.01580.x","volume":"84","author":"SA Farr","year":"2003","unstructured":"Farr SA, Poon HF, Dogrukol-Ak D, Drake J, Banks WA, Eyerman E, et al. The antioxidants alpha-lipoic acid and N-acetylcysteine reverse memory impairment and brain oxidative stress in aged SAMP8 mice. J Neurochem. 2003;84(5):1173\u201383.","journal-title":"J Neurochem"},{"issue":"3","key":"2793_CR24","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.neuint.2012.05.019","volume":"61","author":"C Valdovinos-Flores","year":"2012","unstructured":"Valdovinos-Flores C, Gonsebatt ME. The role of amino acid transporters in GSH synthesis in the blood-brain barrier and central nervous system. Neurochem Int. 2012;61(3):405\u201314.","journal-title":"Neurochem Int"},{"issue":"3","key":"2793_CR25","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.neulet.2011.05.027","volume":"499","author":"OM Dean","year":"2011","unstructured":"Dean OM, van den Buuse M, Berk M, Copolov DL, Mavros C, Bush AI. N-acetyl cysteine restores brain glutathione loss in combined 2-cyclohexene-1-one and d-amphetamine-treated rats: relevance to schizophrenia and bipolar disorder. Neurosci Lett. 2011;499(3):149\u201353.","journal-title":"Neurosci Lett"},{"key":"2793_CR26","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.neubiorev.2015.04.015","volume":"55","author":"Deepmala","year":"2015","unstructured":"Deepmala, Slattery J, Kumar N, Delhey L, Berk M, Dean O, et al. Clinical trials of N-acetylcysteine in psychiatry and neurology: A systematic review. Neurosci Biobehav Rev. 2015;55:294\u2013321.","journal-title":"Neurosci Biobehav Rev"},{"key":"2793_CR27","first-page":"2469486","volume":"2018","author":"SL Ooi","year":"2018","unstructured":"Ooi SL, Green R, Pak SC. N-Acetylcysteine for the treatment of psychiatric disorders: a review of current evidence. Biomed Res Int. 2018;2018:2469486.","journal-title":"Biomed Res Int"},{"issue":"5","key":"2793_CR28","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.biopsych.2008.03.004","volume":"64","author":"M Berk","year":"2008","unstructured":"Berk M, Copolov D, Dean O, Lu K, Jeavons S, Schapkaitz I, et al. N-acetyl cysteine as a glutathione precursor for schizophrenia--a double-blind, randomized, placebo-controlled trial. Biol Psychiatry. 2008;64(5):361\u20138.","journal-title":"Biol Psychiatry"},{"issue":"6","key":"2793_CR29","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.biopsych.2008.04.022","volume":"64","author":"M Berk","year":"2008","unstructured":"Berk M, Copolov DL, Dean O, Lu K, Jeavons S, Schapkaitz I, et al. N-acetyl cysteine for depressive symptoms in bipolar disorder--a double-blind randomized placebo-controlled trial. Biol Psychiatry. 2008;64(6):468\u201375.","journal-title":"Biol Psychiatry"},{"issue":"3","key":"2793_CR30","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1037\/pas0000486","volume":"30","author":"FW Weathers","year":"2018","unstructured":"Weathers FW, Bovin MJ, Lee DJ, Sloan DM, Schnurr PP, Kaloupek DG, et al. The clinician-administered PTSD scale for DSM-5 (CAPS-5): development and initial psychometric evaluation in military veterans. Psychol Assess. 2018;30(3):383\u201395.","journal-title":"Psychol Assess"},{"issue":"6","key":"2793_CR31","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1111\/j.1600-0447.1983.tb09716.x","volume":"67","author":"AS Zigmond","year":"1983","unstructured":"Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983;67(6):361\u201370.","journal-title":"Acta Psychiatr Scand"},{"key":"2793_CR32","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1136\/jnnp.23.1.56","volume":"23","author":"M Hamilton","year":"1960","unstructured":"Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23:56\u201362.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"6","key":"2793_CR33","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1002\/jts.22059","volume":"28","author":"CA Blevins","year":"2015","unstructured":"Blevins CA, Weathers FW, Davis MT, Witte TK, Domino JL. The posttraumatic stress disorder checklist for DSM-5 (PCL-5): development and initial psychometric evaluation. J Trauma Stress. 2015;28(6):489\u201398.","journal-title":"J Trauma Stress"},{"issue":"2","key":"2793_CR34","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1097\/00006842-200203000-00008","volume":"64","author":"K Kroenke","year":"2002","unstructured":"Kroenke K, Spitzer RL, Williams JB. The PHQ-15: validity of a new measure for evaluating the severity of somatic symptoms. Psychosom Med. 2002;64(2):258\u201366.","journal-title":"Psychosom Med"},{"issue":"2","key":"2793_CR35","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1023\/B:QURE.0000018486.91360.00","volume":"13","author":"SM Skevington","year":"2004","unstructured":"Skevington SM, Lotfy M, O'Connell KA, Group W. The World Health Organization's WHOQOL-BREF quality of life assessment: psychometric properties and results of the international field trial. A report from the WHOQOL group. Qual Life Res. 2004;13(2):299\u2013310.","journal-title":"Qual Life Res"},{"issue":"6","key":"2793_CR36","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1111\/j.1360-0443.1993.tb02093.x","volume":"88","author":"JB Saunders","year":"1993","unstructured":"Saunders JB, Aasland OG, Babor TF, de la Fuente JR, Grant M. Development of the alcohol use disorders identification test (AUDIT): WHO collaborative project on early detection of persons with harmful alcohol consumption--II. Addiction. 1993;88(6):791\u2013804.","journal-title":"Addiction."},{"issue":"Suppl 20","key":"2793_CR37","first-page":"22","volume":"59","author":"DV Sheehan","year":"1998","unstructured":"Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998;59(Suppl 20):22\u201333 quiz 4\u201357.","journal-title":"J Clin Psychiatry"},{"issue":"5","key":"2793_CR38","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1001\/jama.2015.8370","volume":"314","author":"MM Steenkamp","year":"2015","unstructured":"Steenkamp MM, Litz BT, Hoge CW, Marmar CR. Psychotherapy for military-related PTSD: a review of randomized clinical trials. JAMA. 2015;314(5):489\u2013500.","journal-title":"JAMA."},{"issue":"4","key":"2793_CR39","doi-asserted-by":"crossref","first-page":"e457","DOI":"10.4088\/JCP.15r09984","volume":"77","author":"BS Fernandes","year":"2016","unstructured":"Fernandes BS, Dean OM, Dodd S, Malhi GS, Berk M. N-Acetylcysteine in depressive symptoms and functionality: a systematic review and meta-analysis. J Clin Psychiatry. 2016;77(4):e457\u201366.","journal-title":"J Clin Psychiatry."},{"issue":"3","key":"2793_CR40","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.tips.2013.01.001","volume":"34","author":"M Berk","year":"2013","unstructured":"Berk M, Malhi GS, Gray LJ, Dean OM. The promise of N-acetylcysteine in neuropsychiatry. Trends Pharmacol Sci. 2013;34(3):167\u201377.","journal-title":"Trends Pharmacol Sci"},{"issue":"11","key":"2793_CR41","doi-asserted-by":"crossref","first-page":"e1439","DOI":"10.4088\/JCP.15m10239","volume":"77","author":"SE Back","year":"2016","unstructured":"Back SE, McCauley JL, Korte KJ, Gros DF, Leavitt V, Gray KM, et al. A double-blind, randomized, controlled pilot trial of N-Acetylcysteine in veterans with posttraumatic stress disorder and substance use disorders. J Clin Psychiatry. 2016;77(11):e1439\u2013e46.","journal-title":"J Clin Psychiatry."},{"issue":"6","key":"2793_CR42","doi-asserted-by":"crossref","first-page":"628","DOI":"10.4088\/JCP.13m08454","volume":"75","author":"M Berk","year":"2014","unstructured":"Berk M, Dean OM, Cotton SM, Jeavons S, Tanious M, Kohlmann K, et al. The efficacy of adjunctive N-acetylcysteine in major depressive disorder: a double-blind, randomized, placebo-controlled trial. J Clin Psychiatry. 2014;75(6):628\u201336.","journal-title":"J Clin Psychiatry"},{"issue":"2","key":"2793_CR43","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1176\/appi.ajp.162.2.214","volume":"162","author":"R Bradley","year":"2005","unstructured":"Bradley R, Greene J, Russ E, Dutra L, Westen D. A multidimensional meta-analysis of psychotherapy for PTSD. Am J Psychiatry. 2005;162(2):214\u201327.","journal-title":"Am J Psychiatry"},{"issue":"5","key":"2793_CR44","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1002\/da.22469","volume":"33","author":"A De Jongh","year":"2016","unstructured":"De Jongh A, Resick PA, Zoellner LA, van Minnen A, Lee CW, Monson CM, et al. Critical analysis of the current treatment guidelines for complex Ptsd in adults. Depress Anxiety. 2016;33(5):359\u201369.","journal-title":"Depress Anxiety"},{"issue":"6","key":"2793_CR45","doi-asserted-by":"crossref","first-page":"e541","DOI":"10.4088\/JCP.12r08225","volume":"74","author":"BV Watts","year":"2013","unstructured":"Watts BV, Schnurr PP, Mayo L, Young-Xu Y, Weeks WB, Friedman MJ. Meta-analysis of the efficacy of treatments for posttraumatic stress disorder. J Clin Psychiatry. 2013;74(6):e541\u201350.","journal-title":"J Clin Psychiatry."},{"issue":"2","key":"2793_CR46","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1177\/2167702614545480","volume":"3","author":"EJ Wolf","year":"2015","unstructured":"Wolf EJ, Miller MW, Kilpatrick D, Resnick HS, Badour CL, Marx BP, et al. ICD-11 complex PTSD in US national and veteran samples: prevalence and structural associations with PTSD. Clin Psychol Sci. 2015;3(2):215\u201329.","journal-title":"Clin Psychol Sci"}],"container-title":["BMC Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-020-02793-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12888-020-02793-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-020-02793-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,5]],"date-time":"2021-08-05T23:34:35Z","timestamp":1628206475000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpsychiatry.biomedcentral.com\/articles\/10.1186\/s12888-020-02793-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,6]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["2793"],"URL":"https:\/\/doi.org\/10.1186\/s12888-020-02793-9","relation":{},"ISSN":["1471-244X"],"issn-type":[{"value":"1471-244X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,6]]},"assertion":[{"value":"24 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This project has been approved by the Human Research Ethics Committees of Austin Health (approval 16\/Austin\/188) and The Melbourne Clinic (approval 305). All participants will give written informed consent.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"MB is supported by a NHMRC Senior Principal Research Fellowship (1059660 and 1156072).MB has received Grant\/Research Support from the NIH, Cooperative Research Centre, Simons Autism Foundation, Cancer Council of Victoria, Stanley Medical Research Foundation, Medical Benefits Fund, National Health and Medical Research Council, Medical Research Futures Fund, Beyond Blue, Rotary Health, A2 milk company, Meat and Livestock Board, Woolworths, Avant and the Harry Windsor Foundation, has been a speaker for Astra Zeneca, Lundbeck, Merck, Pfizer, and served as a consultant to Allergan, Astra Zeneca, Bioadvantex, Bionomics, Collaborative Medicinal Development, Lundbeck Merck, Pfizer and Servier \u2013 all unrelated to this work.CN has served as a consultant for Lundbeck, Grunbiotics, Servier, Janssen-Cilag, Wyeth and Eli Lilly, received research grant support from Wyeth and Lundbeck, and speaker honoraria from Servier, Lundbeck, Bristol-Myers Squibb, Organon, Eli Lilly, GlaxoSmithKline, Janssen- Cilag, Astra-Zenaca, Wyeth, and Pfizer.The other authors declare they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"397"}}